A practical reference on circadian rhythm: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-07-30 and is reviewed periodically as new material appears.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
The α-decay half-life of 240Cm was determined as 26.8 days and later revised to 30.4 days. The discovery of curium and americium in 1944 was closely related to the Manhattan Project, so the results were confidential and declassified only in 1945. Seaborg leaked the synthesis of the elements 95 and 96 on the U.S. radio show for children, the Quiz Kids, five days before the official presentation at an American Chemical Society meeting on November 11, 1945, when one listener asked if any new transuranic element beside plutonium and neptunium had been discovered during the war. The discovery of curium (242Cm and 240Cm), its production, and its compounds was later patented listing only Seaborg as the inventor.
== History == Ziprasidone is chemically similar to risperidone, of which it is a structural analogue. It was first synthesized in 1987 at the Pfizer central research campus in Groton, Connecticut. Phase I trials started in 1995. In 1998 ziprasidone was approved in Sweden. After the FDA raised concerns about long QT syndrome, more clinical trials were conducted and submitted to the FDA, which approved the drug on February 5, 2001.
There are several Akabori amino acid reactions, which are named after Shirō Akabori (Japanese: 赤堀 四郎) (1900–1992), a Japanese chemist. In the first reaction, an α-amino acid is oxidised and undergoes decarboxylation to give an aldehyde at the former α position by heating with oxygen in the presence of a reducing sugar. This reaction is useful for preparing dichlorophthalimido derivatives of peptides for mass spectral analysis.
On April 9, 1953, Giáp, after having failed repeatedly in direct attacks on French positions in Vietnam, changed strategy and began to pressure the French by invading Laos, surrounding and defeating several French outposts such as Muong Khoua. In May, General Henri Navarre replaced Salan as supreme commander of French forces in Indochina. He reported to the French government "... that there was no possibility of winning the war in Indo-China", saying that the best the French could hope for was a stalemate. Through the Navarre Plan, French forces and the Vietnamese National Army sought to use their advantage in technology and arms to hold cities and key roads, thereby hoping to force the Việt Minh into an impasse and negotiation. Per this strategy, French forces fortified the town of Điện Biên Phủ in an effort to block the Việt Minh's connections with Laos and Việt Minh bases there. The town was located along a main route between Hanoi and Vientiane and was ringed by mountains. Operation Castor was launched on November 20, 1953, with 1,800 men of the French 1st and 2nd Airborne Battalions dropping into the valley of Điện Biên Phủ and sweeping aside the local Việt Minh garrison. The paratroopers gained control of a heart-shaped valley 12 miles (19 km) long and 8 miles (13 km) wide surrounded by heavily wooded mountains. Encountering little opposition, the French and Tai units operating from Lai Châu to the north patrolled the mountains. The operation was a tactical success for the French.
Sources: en.wikipedia.org
Several historical figures may have died from A. phalloides poisoning (or other similar toxic Amanita species). These were either accidental poisonings or assassination plots. Alleged victims of this kind of poisoning include Roman Emperor Claudius, Pope Clement VII, the Russian tsaritsa Natalia Naryshkina, and Holy Roman Emperor Charles VI. R. Gordon Wasson recounted the details of these deaths, noting the likelihood of Amanita poisoning. In the case of Clement VII, the illness that led to his death lasted five months, making the case inconsistent with amatoxin poisoning. Natalya Naryshkina is said to have consumed a large quantity of pickled mushrooms prior to her death. It is unclear whether the mushrooms themselves were poisonous or if she succumbed to food poisoning. Charles VI, Holy Roman Emperor experienced indigestion after eating a dish of sautéed mushrooms in October 1740. This led to an illness from which he died 10 days later—symptomatology consistent with amatoxin poisoning. His death caused the end of the agnatic line of the House of Habsburg and led to the War of the Austrian Succession. Noted Voltaire, "this mushroom dish has changed the destiny of Europe." The case of Claudius's poisoning is more complex. Claudius was known to have been very fond of eating Caesar's mushroom. Following his death, many sources have attributed it to his being fed a meal of death caps instead of Caesar's mushrooms.
As noted above, in radioactive decay the half-life is the length of time after which there is a 50% chance that an atom will have undergone nuclear decay. It varies depending on the atom type and isotope, and is usually determined experimentally. See List of nuclides. The current flowing through an RC circuit or RL circuit decays with a half-life of ln(2)RC or ln(2)L/R, respectively. For this example the term half time tends to be used rather than "half-life", but they mean the same thing. In a chemical reaction, the half-life of a species is the time it takes for the concentration of that substance to fall to half of its initial value. In a first-order reaction the half-life of the reactant is ln(2)/λ, where λ (also denoted as k) is the reaction rate constant.
== Industrial requirements for an extracting agent == The European experience in nuclear partitioning led to advanced hydrometallurgical separation processes. However, the feasibility of these advanced partitioning processes at industrial level relies on the use of reliable and affordable extracting agents, which have to meet these relevant industrial requirements:
Early research in the 19th and 20th centuries on osmosis and diffusion provided the foundation for understanding the passive movement of molecules across cell membranes. In 1855, the physiologist Adolf Fick was the first to define osmosis and simple diffusion as the tendency for solutes to move from a region of higher concentration to a lower concentration, also very well-known as Fick's Laws of Diffusion. Through the work of Charles Overton in the 1890s, the concept that the biological membrane is semipermeable became important to understanding the regulation of substances in and out of the cells. The discovery of facilitated diffusion by Wittenberg and Scholander suggested that proteins in the cell membrane aid in the transport of molecules. In the 1960s - 1970s, studies on the transport of glucose and other nutrients highlighted the specificity and selectivity of membrane transport proteins. Technological advancements in biochemistry helped isolate and characterize these proteins from cell membranes. Genetic studies on bacteria and yeast identified genes responsible for encoding transporters. This led to the discovery of glucose transporters (GLUT proteins), with GLUT1 being the first to be characterized. Identification of gene families encoding various transporters, such as solute carrier (SLC) families, also advanced knowledge on uniporters and its functions. Newer research is focusing on techniques using recombinant DNA technology, electrophysiology and advanced imaging to understand uniporter functions.
In 1913, as part of his exploration into the composition of canal rays, J. J. Thomson channeled a stream of ionized neon through a magnetic and an electric field and measured its deflection by placing a photographic plate in its path. Thomson observed two patches of light on the photographic plate (see image on left), which suggested two different parabolas of deflection. Thomson concluded that the neon gas was composed of atoms of two different atomic masses (neon-20 and neon-22). Thomson's student Francis William Aston continued the research at the Cavendish Laboratory in Cambridge, building the first full functional mass spectrometer that was reported in 1919. He was able to identify isotopes of chlorine (35 and 37), bromine (79 and 81), and krypton (78, 80, 82, 83, 84 and 86), proving that these natural occurring elements are composed of a combination of isotopes. The use of electromagnetic focusing in mass spectrograph which rapidly allowed him to identify no fewer than 212 of the 287 naturally occurring isotopes. In 1921, F. W. Aston became a fellow of the Royal Society and received a Nobel Prize in Chemistry in the following year. His work on isotopes also led to his formulation of the Whole Number Rule which states that "the mass of the oxygen isotope being defined [as 16], all the other isotopes have masses that are very nearly whole numbers," a rule that was used extensively in the development of nuclear energy.
Sources: en.wikipedia.org
Carbon dioxide content in fresh air (averaged between sea-level and 10 kPa level, i.e., about 30 km (19 mi) altitude) varies between 0.036% (360 ppm) and 0.041% (412 ppm), depending on the location. In humans, exposure to CO2 at concentrations greater than 5% causes the development of hypercapnia and respiratory acidosis. Concentrations of 7% to 10% (70,000 to 100,000 ppm) may cause suffocation, even in the presence of sufficient oxygen, manifesting as dizziness, headache, visual and hearing dysfunction, and unconsciousness within a few minutes to an hour. Concentrations of more than 10% may cause convulsions, coma, and death. CO2 levels of more than 30% act rapidly leading to loss of consciousness in seconds. Because it is heavier than air, in locations where the gas seeps from the ground (due to sub-surface volcanic or geothermal activity) in relatively high concentrations, without the dispersing effects of wind, it can collect in sheltered/pocketed locations below average ground level, causing animals located therein to be suffocated. Carrion feeders attracted to the carcasses are then also killed. Children have been killed in the same way near the city of Goma by CO2 emissions from the nearby volcano Mount Nyiragongo. The Swahili term for this phenomenon is mazuku.
Polycystic Ovary Syndrome A previous diagnosis of gestational diabetes or prediabetes, impaired glucose tolerance, or impaired fasting glycaemia A family history revealing a first-degree relative with type 2 diabetes Maternal age – a woman's risk factor increases as she gets older (especially for women over 35 years of age). Paternal age – one study found that a father's age over 55 years was associated with GD Ethnicity (those with higher risk factors include African Americans, Afro-Caribbeans, Native Americans, Hispanics, Pacific Islanders, and people originating from South Asia) Being overweight, obese, or severely obese increases the risk by a factor of 2.1, 3.6, and 8.6, respectively. A previous pregnancy which resulted in a child with a macrosomia (high birth weight: >90th centile or >4000 g (8 lbs 12.8 oz)) Previous poor obstetric history Other genetic risk factors: There are at least 10 genes where certain polymorphism are associated with an increased risk of gestational diabetes, most notably TCF7L2. The MTNR1B gene is a common gene that is associated with how the body handles insulin and glucose. When this gene is not working properly, it can lead to less insulin production and higher blood glucose levels. In addition to this, statistics show a double risk of GDM in smokers. Some studies have looked at more controversial potential risk factors, such as short stature. About 40–60% of women with GDM have no demonstrable risk factor; for this reason, many advocate for screening all women.
== External links == Actin Staining Techniques (Live and Fixed Cell Staining) Eukaryotic Linear Motif resource motif class LIG_Actin_RPEL_3 Eukaryotic Linear Motif resource motif class LIG_Actin_WH2_1 Eukaryotic Linear Motif resource motif class LIG_Actin_WH2_2 3D macromolecular structures of actin filaments from the EM Data Bank(EMDB)
Scattering data is usually represented in terms of the so-called excess Rayleigh ratio defined as the Rayleigh ratio of the solution or single particle event from which is subtracted the Rayleigh ratio of the carrier fluid itself and other background contributions, if any. The Rayleigh Ratio measured at a detector lying at an angle θ and subtending a solid angle ΔΩ is defined as the intensity of light per unit solid angle per unit incident intensity, I0, per unit illuminated scattering volume ΔV. The scattering volume ΔV from which scattered light reaches the detector is determined by the detector's field of view generally restricted by apertures, lenses and stops. Consider now a MALS measurement made in a plane from a suspension of N identical particles/molecules per ml illuminated by a fine beam of light produced by a laser. Assuming that the light is polarized perpendicular to the plane of the detectors. The scattered light intensity measured by the detector at angle θ in excess of that scattered by the suspending fluid would be
It is also possible to translate either by hand (for short sequences) or by computer (after first programming one appropriately, see section below); this allows biologists and chemists to draw out the primary amino acid sequence of the encoded protein on paper. First, convert each template DNA base to its RNA complement (note that the complement of A is now U), as shown below. Note that the template strand of the DNA is the one the RNA is polymerized against; the other DNA strand would be the same as the RNA, but with thymine instead of uracil.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.